Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1862 results
February 2022
-
Press Release
Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines1,4Cost savings from Lenalidomide Sandoz can expand treatment options for… -
Statement
Novartis announces European Patent Office orders grant of the European Gilenya® (fingolimod) 0.5mg daily dose patent
-
Featured News
Novartis Co-Creating Impact Summit 2021
Over 1,800 delegates came together at the annual Co-Creating Impact Summit to explore how understanding ‘impact’ is a crucial step in ensuring business makes a positive contribution to the world.
-
Key Release
Novartis erzielt 2021 ein Umsatzwachstum im mittleren einstelligen Bereich, verbessert die Margen und treibt die solide Pipeline voran
Ad-hoc-Mitteilung gemäss Art. 53 KR Im vierten Quartal stieg der Umsatz um +6% (kWk1, +4% USD), das operative Kernergebnis wuchs um +12% (kWk, +9% USD) Innovative Medicines steigerte den… -
Key Release
Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021
Ad hoc announcement pursuant to Art. 53 LR Q4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD) IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12… -
Key Release
Novartis: a enregistré, en 2021, une croissance du chiffre d’affaires net à un chiffre dans le milieu de la fourchette, une expansion de la marge et une avancée du robuste pipeline
Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du 4e trimestre en hausse de +6% (tcc1, +4% USD) et résultat opérationnel core croissant de +12% (tcc1, +9% USD) Innovative…
January 2022
-
Statement
2021 Global Managed Access Program Community Update
-
Press Release
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
Topline results from the randomized EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo,… -
Press Release
Novartis announces collaboration with Alnylam to explore targeted therapy to restore liver function
Agreement will bring Alnylam’s proprietary siRNA technology to bear on liver target identified by Novartis researchers Novartis and Alnylam have agreed to collaborate on discovery and development of… -
Press Release
Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent
Basel, January 4, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its decision upholding the validity of US Patent No. 9,187,405 covering a…